Native LDL
lipoproteinApoB-lipoprotein subclass retained in subendothelial intima; substrate for oxidative modification initiating atherosclerosis.
Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleKey atherogenic lipoprotein; proatherosclerotic hyperlipidemia driver.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I49
C — confounder / Type-II32
A — assay feasibility82
E — evidence strength19
T1DI (composite)9
Specificity differential (R−C)+17.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Specialized reference method
Specimen
Serum or plasma (EDTA)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
NMR lipoprotein particle analysis or density-gradient ultracentrifugation
Reagent / substrate
No chemical reagent — NMR spectral deconvolution of lipid methyl signals (or ultracentrifugal separation by density)
Platform
NMR (LabCorp NMR LipoProfile) / analytical ultracentrifuge
Turnaround · availability
Send-out · Specialized reference lab
Literature evidence(1)
- Platelets as an inter-player between hyperlipidaemia and atherosclerosis.Journal of internal medicine · 2024 · PMID 38704820 · doi